FDA label
What is Vimpat used for?
Vimpat contains lacosamide. The FDA-approved uses below are quoted from the Indications and Usage section of its DailyMed label.
Source: DailyMed SPL label file dated 2026-10-23. Publisher page
The FDA label for Vimpat lists 2 uses: Partial-Onset Seizures; Primary Generalized Tonic-Clonic Seizures.
Run it in Rivvi
Which 2027 plans near you dropped or restricted Vimpat?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Vimpat, tablet, film coated
Indications and Usage, quoted from the label by UCB, Inc. (NDA022253). Cross-references to other label sections are left out.
Partial-Onset Seizures
VIMPAT is indicated for the treatment of partial-onset seizures in patients 1 month of age and older.
Primary Generalized Tonic-Clonic Seizures
VIMPAT is indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older.
Source: DailyMed label, set id 9e79b42c-38a3-4b2c-a196-a5a1948250e2, version 63, effective May 12, 2026. NDC 0131-2477, one of 4 listings for this product.
Questions
What is Vimpat used for?
The FDA label for Vimpat lists 2 uses: Partial-Onset Seizures; Primary Generalized Tonic-Clonic Seizures.
Does this page cover off-label uses or dosing?
No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.
More on Vimpat
- Is Vimpat a controlled substance?Schedule V
- Generic for VimpatFDA Orange Book
- What is Lacosamide used for?FDA label uses
- Is Lacosamide a controlled substance?Schedule V
- Generic for Motpoly XRFDA Orange Book
- NDC 0131-1810Vimpat NDC record
- NDC 0131-2477Vimpat NDC record
- NDC 0131-2478Vimpat NDC record
- Schedule V drugs listDEA schedule